Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity

NCT04222790 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04222790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04222790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized Controlled Phase II Clinical Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2020
Completion date
April 21, 2022
Enrollment
159 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer